Skip to content
Subscribe Follow on LinkedIn

Press Release

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

✨ Onyx Summary Lexicon Pharmaceuticals announced that new data from three studies of sotagliflozin will be presented at the 2025 American Heart Association Scientific Sessions and the Hypertrophic Cardiomyopathy Society conference in New Orleans. The presentations will highlight sotagliflozin’s effects in heart failure and hypertrophic cardiomyopathy, reinforcing its potential differentiation

Recursion to Participate in Upcoming Investor Conferences

Recursion to Participate in Upcoming Investor Conferences

✨ Onyx Summary Recursion announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11 and the Jefferies Global Healthcare Conference in London on November 18, 2025. Live webcasts of both events will be available on the company’s investor relations website. Salt Lake City, Nov. 04, 2025

Geron Corporation to Present at Upcoming Investor Conferences

Geron Corporation to Present at Upcoming Investor Conferences

✨ Onyx Summary Geron announced that CEO Harout Semerjian will participate in fireside chats at the Stifel 2025 Healthcare Conference on November 11 and the 8th Annual Evercore Healthcare Conference on December 2. Live and archived webcasts of both sessions will be available on the company’s investor relations website. FOSTER

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

✨ Onyx Summary Phathom Pharmaceuticals announced dosing of the first patient in its Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA (vonoprazan) tablets as a potential treatment for eosinophilic esophagitis in adults. The randomized, placebo-controlled study aims to assess VOQUEZNA’s efficacy and safety as a non-steroidal oral therapy for EoE, with topline

enGene Named a BioSpace 2026 Best Places to Work Winner

enGene Named a BioSpace 2026 Best Places to Work Winner

✨ Onyx Summary enGene Holdings was named to BioSpace’s 2026 Best Places to Work list, recognizing it among the top 50 U.S. life sciences employers for workplace culture and employee engagement. The honor reflects enGene’s continued growth and mission-driven focus as it advances its late-stage non-viral gene therapy,

Guardant Health Announces Proposed Public Offering of Common Stock

Guardant Health Announces Proposed Public Offering of Common Stock

✨ Onyx Summary Guardant Health launched a $250 million underwritten public offering of its common stock, with an additional $37.5 million option for underwriters, to be managed by Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities. Proceeds, alongside funds from a concurrent $300 million convertible notes offering, will be used

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

✨ Onyx Summary Geron announced five presentations at the 2025 American Society of Hematology Annual Meeting, including new clinical and translational data on RYTELO (imetelstat) in lower-risk myelodysplastic syndromes and myelofibrosis. The presentations highlight long-term efficacy results from the Phase 3 IMerge trial and new analyses linking imetelstat’s biological activity

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

✨ Onyx Summary Phathom Pharmaceuticals announced its management team will participate in multiple investor conferences in November and December 2025, including events hosted by Guggenheim, Stifel, Jefferies, Craig-Hallum, and Evercore. Live and archived webcasts of select presentations will be available on the company’s investor relations website for 90 days following

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

✨ Onyx Summary Foghorn Therapeutics announced management participation in three upcoming investor events—the Guggenheim Healthcare Innovation, Stifel 2025 Healthcare, and Jefferies 2025 London Healthcare Conferences—featuring presentations by CEO Adrian Gottschalk. The company will use these forums to engage investors and highlight progress of its Gene Traffic Control® platform and

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

✨ Onyx Summary Belite Bio (NASDAQ: BLTE) said the UK MHRA will accept a Conditional Marketing Authorization application for Tinlarebant in Stargardt disease based on interim Phase 3 DRAGON results, with final topline data expected in Q4 2025 for subsequent full MAA submission. The pivotal DRAGON trial enrolled 104 adolescent patients

Perspective Therapeutics to Participate in Upcoming November Conferences

Perspective Therapeutics to Participate in Upcoming November Conferences

✨ Onyx Summary Perspective Therapeutics (NYSE American: CATX) announced its senior leadership will participate in the Truist Securities BioPharma Symposium on November 6, 2025, and the UBS Global Healthcare Conference on November 11, 2025, where it will host a fireside chat. The company continues to engage the investment community as it